What We Do: Improve patient outcomes through science that describes the spatial and temporal evolution of the disease in each patient. Leverage single cell genomics and single cell proteomics (aka ‘no cell left behind’). Connect clinical and research data through mathematical models.
Jorge Nieva, MD / Kuhn lab kickoff ATOM-HP
Jeremy Mason (Postdoc) published in npj Breast Cancer
Drs. Kuhn and Hicks Featured in the Huffington Post
Kuhn Lab Students Awarded Provost's Research Fellowships
The Analytical Tools to Objectively Measure Human Performance (ATOM-HP) program is a two year pilot project between the National Cancer Institute’s Center for Strategic Initiatives and the... Read More
“CTC-based diagnostics are ready for prime time,” Murali Prahalad, CEO of Epic Sciences said. “We’re carrying out molecular analyses, with clonal resolution and assessment of protein, FISH and NGS, gaining insights that were not possible before from malignant cells in blood samples.”
“We look at the individual cells from patients’ blood in real time, and interrogate specific pathway points. This way, we can rationally assign cancer drugs.”
Epic Sciences no cell left behind™ technology is a powerful rare-cell detection and characterization platform, which was founded on unique technology from Dr. Peter Kuhn's lab.
Congratulations to our melanoma team! The work entitled “Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients” by Carmen Ruiz et al. was included in a selection of papers published by Physical Biology representing the breadth and excellence of current research on the physics of cancer.
Carmen Ruiz1, Julia Li1, Madelyn S Luttgen1, Anand Kolatkar1, Jude T Kendall6, Edna Flores2, Zheng Topp2, Wolfram E Samlowski3, Edward McClay4, Kelly Bethel2, Soldano Ferrone5, James Hicks6 and Peter Kuhn7